Create a narrative

Edwards Lifesciences Community

NYSE:EW Community

1 Narratives written by author
0 Comments on narratives written by author
56 Fair Values set on narratives written by author

Edwards Lifesciences

AN

AnalystConsensusTarget

AnalystConsensusTarget

Consensus Narrative from 30 Analysts

Early TAVR And EVOQUE Launches Will Expand Access

Key Takeaways Strategic product launches, like the TAVR approval and EVOQUE, position Edwards for significant revenue growth and expanded market share. Investments in surgical innovation and operational efficiency mitigate financial threats, enhance global therapy adoption, and stabilize earnings.

US$87.12

FV

9.4% undervalued

9.99%

Revenue growth p.a.

0

0

23

7 days ago